What is the recommended treatment for recurrent focal segmental glomerulosclerosis after kidney transplantation?

Treatment of Recurrent FSGS Post Kidney Transplant

Plasma exchange (plasmapheresis) is the first-line treatment for recurrent focal segmental glomerulosclerosis after kidney transplantation, initiated as soon as biopsy confirms recurrence. 1

Initial Management Algorithm

Step 1: Confirm Diagnosis and Initiate Plasma Exchange

• Obtain allograft biopsy when new proteinuria develops (typically >3 g/day) or when graft function deteriorates unexpectedly to confirm recurrent FSGS versus other pathology 1
• Begin therapeutic plasma exchange immediately upon biopsy confirmation, as this is the KDIGO-recommended first-line intervention (Grade 2D) 1
• Continue plasma exchange sessions until spot urine protein:creatinine ratio falls below 0.5, which typically requires multiple sessions over weeks to months 2
• Monitor proteinuria closely during treatment, as approximately 45% reduction per session can be expected with immunoadsorption techniques 3

Step 2: Add Rituximab for Refractory Cases

• Administer rituximab if plasma exchange alone fails to achieve remission after 2-4 weeks of intensive therapy 4
• Dosing varies from low-dose (100 mg single dose) to standard doses (375 mg/m²), with evidence supporting efficacy across this range 5, 4
• The combination of plasma exchange plus rituximab shows superior outcomes compared to either therapy alone, particularly for achieving prolonged remission 4

Maintenance Immunosuppression Adjustments

Calcineurin Inhibitor Optimization

• Continue tacrolimus-based immunosuppression with target trough levels of 5-10 ng/mL (6-12 nmol/L) to balance efficacy against nephrotoxicity 6
• Monitor serum creatinine closely; reduce CNI dose if creatinine increases >30% from baseline and does not plateau 6
• Consider belatacept-based CNI-free regimen in select cases with persistent recurrence despite standard therapy, as this has achieved sustained complete remission in case reports 7

Adjunctive Agents

• Initiate ACE inhibitor or ARB for all patients with recurrent glomerulonephritis and proteinuria to provide renoprotection 1
• Continue mycophenolate mofetil and corticosteroids as part of baseline immunosuppression 6

Alternative and Emerging Therapies

For Plasma Exchange-Dependent or Resistant Disease

• Immunoadsorption with reusable columns can be used as an alternative to conventional plasma exchange, allowing up to 14 sessions per column with similar efficacy 3
• Costimulation blockade with abatacept or belatacept may induce remission in rituximab-refractory cases by targeting B7-1 on podocytes 7

Experimental Approaches (Not Standard of Care)

• Daratumumab and obinutuzumab are explicitly listed as experimental by the American College of Insurance and are not recommended outside clinical trials 1
• These monoclonal antibodies lack guideline support and carry substantial cost ($16,753.50 and $10,335.20 per infusion respectively) without proven efficacy 1

Treatment Duration and Monitoring

Acute Phase

• Intensive plasma exchange typically requires 3-5 sessions per week initially, then tapered based on proteinuria response 3, 2
• Rituximab effects manifest within days to weeks, with B-cell depletion lasting 6-12 months 5, 4

Long-Term Management

• Some patients remain plasma exchange-dependent despite initial response, requiring ongoing maintenance sessions every 2-4 weeks 3
• Monitor for cytomegalovirus reactivation, the most common adverse event with combined immunosuppression and rituximab, requiring valganciclovir prophylaxis or treatment 3

Critical Pitfalls to Avoid

• Do not delay biopsy when significant proteinuria develops; early diagnosis and treatment initiation are crucial for graft salvage 1
• Do not use IVIg as monotherapy, as KDIGO guidelines do not support this approach for recurrent FSGS 1
• Do not discontinue plasma exchange prematurely even if initial response is slow; some patients require 72+ sessions for sustained remission 3
• Do not assume treatment failure if proteinuria persists after 2-3 weeks; continue therapy for at least 4-6 weeks before declaring resistance 3, 2

Expected Outcomes

• Recurrence rate is approximately 47% in patients meeting strict criteria for primary FSGS, rising to 86% in pediatric recipients 4
• Complete or partial remission can be achieved in all patients with intensive plasma exchange and rituximab, though 2 of 7 patients in one series ultimately lost their grafts despite treatment 3
• Graft survival is significantly lower in patients with recurrent FSGS compared to other transplant recipients, making aggressive early intervention essential 4